Evaluation of QTc interval prolongation in patients with advanced clear cell renal cell carcinoma treated with first line sunitinib.
| Publicado en: | Cancer Chemotherapy & Pharmacology Vol. 96; no. 1; pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
9/17/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=197143633&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 197143633 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 03445704 NO9 jtl: Cancer Chemotherapy & Pharmacology issn: 03445704 maglogo: N pubinfo: dt: 9/17/2026 vid: 96 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 197143633 10.1007/s00280-026-04884-y 197143633 ppf: 1 ppct: 11 formats: tig: atl: Evaluation of QTc interval prolongation in patients with advanced clear cell renal cell carcinoma treated with first line sunitinib. aug: au: Sałek-Zań, Agata Püsküllüoğlu, Mirosława Stąpór, Agnieszka Jaworska, Justyna Pietruszka, Agnieszka Grela-Wojewoda, Aleksandra Stąpór, Maciej Banaś, Tomasz affil: https://ror.org/04qcjsm24 Department of Clinical Oncology, Kraków Branch, Maria Sklodowska-Curie National Research Institute of Oncology, Garncarska 11, 31-115, Kraków, Poland sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|